Cellectis S.A.

CLLS
$3.17 (+ $0.18 + 6.12%)
Last updated: 2026-06-10 23:10 UTC
CLLS Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS15117K1034
CUSIP15117K103
Market Price3.17
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.33
Market Cap$476.5M
Book Value1.39
Price to Book3.42
Beta3.04
52w High5.48
52w Low1.1
Next Earnings DateN/A

Cellectis S.A. trades under ticker CLLS on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US15117K1034, CUSIP 15117K103. Also searched as Cellectis.

Related researchCLLS stock priceCLLS share price15117K103Cellectis stockCellectis share price
About the Company
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Price History